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The purpose of this invited review is to summarize the state
of genetic research into the etiology of schizophrenia
(SCZ) and to consider options for progress. The fundamen-
tal uncertainty in SCZ genetics has always been the nature
of the beast, the underlying genetic architecture. If this
were known, studies using the appropriate technologies
and sample sizes could be designed with an excellent chance
of producing high-confidence results. Until recently, few
pertinent data were available, and the field necessarily re-
lied on speculation. However, for the first time in the com-
plex and frustrating history of inquiry into the genetics of
SCZ, we now have empirical data about the genetic basis of
SCZ that implicate specific loci and that can be used to




What are the Goals of Genetic Studies of SCZ?
The major goal of SCZ genetic research is to develop
a complete list of genetic loci and pathways that confer
risk or protection. Given how little we know for certain
about this enigmatic, clinically heterogeneous, and genet-
ically complex disorder, even one unequivocal insight
would be of immense value. The enormous advantage
of genetic studies compared with virtually all other
human biomarker studies is that the key element of cau-
sation is present: exposure to a genetic risk factor begins
at conception and prior to disease onset, and thus tem-
porality is satisfied.
The second but more distal goal requires completion of
the first: to reduce SCZ incidence, to minimize time-to-
treatment for incident cases, and to reduce morbidity
and mortality in cases with SCZ. We stress that this is
an ultimate and not a proximal goal.
Where Have We Been?
A number of reviews of the history of genetic approaches
to SCZ are available.1 Table 1 summarizes the main
approaches. Prior to 2008, 6 methodological approaches
were predominant.
First, generations of physicians have evaluated the family
histories of probands with SCZ. It is notable that this in-
formal surveillance network has not identified any pedigree
with SCZ segregating in a Mendelian fashion. This stands in
contrast to many other complex traits where Mendelian
subforms have been identified. For example, small propor-
tions of cases with breast cancer, Alzheimer’s disease, and
type 2 diabetes mellitus (T2DM) are caused by single gene
mutations that have very high penetrance and are typified
by early age of onset. Notably, genetic evaluation of child-
hood-onset SCZ cases has not yielded causal mutations.17
Because the clinical surveillance network has been nonsys-
tematic, the main conclusion can only be that SCZ is un-
likely to have Mendelian subforms.
Second, a large body of genetic epidemiological studies
has provided the rough outlines of the genetic architec-
ture of SCZ. There is strong but indirect evidence that
SCZ is familial and highly heritable. Third, application
of segregation analysis to SCZ pedigree data has been in-
conclusive. Consistent with inference from the clinical
surveillance network, it is possible to reject a few extreme
models (eg, exclusively dominant or recessive Mendelian
models). However, many other genetic models are consis-
tent with the data.
Fourth, evaluation of ‘‘microscopic’’ genomic changes
using cytogenetic methods has been informative. The
most notable finding was the identification of the
22q11.2 deletion, a rare, potent, and nonspecific risk
factor for SCZ. Its prevalence in cases is ;0.3% with
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genotypic relative risk of ;20.18 This deletion does
not act in a Mendelian fashion: a minority of individuals
with this deletion develops SCZ and it increases risk for
multiple other neuropsychiatric disorders along with the
somatic features of velo-cardiofacial syndrome.19
Fifth, there have been over 30 genome-wide linkage
studies of SCZ along with a meta-analysis.9 No genomic
region emerged that exceeded genome-wide significance
and which was reproducible across studies. These results
are typical for complex biomedical diseases.
Sixth, hypothesis-driven candidate gene studies have
been a major focus in SCZ research with the SZGene da-
tabase listing >1400 studies since 196520 (for comparison,
there are ;2200 PubMed citations for ‘‘SCZ randomized
controlled trials’’). This body of work has not yielded
associations that meet modern criteria for replication.21
Indeed, the nonsystematic nature of this search has led to
mistakes (eg, TCF4 has strong evidence of association
with SCZ and yet has multiple negative studies of
the wrong variant). There are major problems with the
hypothesis-driven candidate gene approach.
 The information content of our hypotheses about SCZ
is unclear. It is possible that many ideas that have dom-
inated the field are at least partially incorrect. More
generally, high-confidence genetic results have poor
correspondence with prior hypotheses about etiology
for most complex traits. T2DM has a wealth of advan-
tages over SCZ (a biochemically defined case defini-
tion, Mendelian subforms, accessible human tissues,
valid animal models, more sophisticated knowledge
of its biology, greater funding, and more research
groups) and yet the ideas that guided hypothesis-
driven candidate gene studies correspond poorly
with the current list of genes very strongly implicated
in its etiology. SCZ has every disadvantage compared
with T2DM: is it plausible that our hypotheses about
SCZ are more likely to correspond to the genetic
underpinnings?
Table 1. Genetic Approaches to SCZ and Broad Conclusions
Method Basis Conclusions
Clinical surveillance The clinical process of physicians taking
family histories. No DNA analysis.
Over past 100 years, no pedigrees with
unequivocal Mendelian inheritance
reported
Genetic epidemiology Diagnosis of SCZ in various types of
relatives (family, twin, adoption). No
DNA analysis.
Family history an important SCZ risk
factor
Most SCZ sporadic (>90%)
SCZ familial: ksibs 8.6 (7.9–9.6)
SCZ heritable: 81% (73–90%)
Segregation analysis What inheritance models are statistically
consistent with observed diagnoses of
SCZ in pedigrees? No DNA analysis.
Uninformative, many different models
consistent with data
Cytogenetics Search for genomic changes in SCZ cases
using karyotyping (3 Mb or larger)
Deletion of 22q11.2 is a rare, potent, and
nonspecific risk factor for SCZ
Genome-wide linkage Attempt at an unbiased genome search for
regions whose inheritance in pedigrees is
correlated with SCZ
No findings meeting modern criteria for
significance and replication
Candidate gene association Evaluation of frequencies of genetic
variation in SCZ cases vs controls for
genes selected using prior hypotheses
about SCZ etiology
Major research focus but no findings
meeting modern criteria for significance
and replication, most studies with serious
methodological issues
Genome-wide association Attempt at unbiased genome search for loci
with differing frequencies in SCZ cases vs
controls
Multiple regions meeting modern criteria
for significance and replication
Evidence that SCZ is highly polygenic
No common variants of strong effect
CNVs Search for genomic changes in SCZ cases vs
controls (resolution variable but can be
100 kb or smaller)
Multiple regions that are rare, relatively
potent, and nonspecific risk factors for
SCZ (22q11.2, 15q13.3, 16p11.2, 1q21.1,
NRXN1)
Resequencing Use high-throughput methods to
resequence regions, exomes, or genomes
to identify SNPs, indels, and CNVs with
differing frequencies (individually or in
aggregate) in SCZ cases vs controls
Initial studies in progress
Note: Literature cited: genetic epidemiology,2–5 segregation analysis,6,7 cytogenetics,8 genome-wide linkage,9 candidate gene association




 Multiple comparison control (type 1 error) requires
scrupulous attention to enumerating every hypothesis
tested.22 This is easy to do in genome-wide association
studies (GWAS) but may not have been a general fea-
ture in the candidate gene literature.
 Statistical power (type 2 error) is generally very low in
the SCZ hypothesis-driven candidate gene literature.
Even for relatively large studies (ie, samples sizes at
the 90th percentiles of Ncase = 537 and Ncontrol = 628
from the SZGene database), a liberal correction for
multiple comparisons (a = 0.005, 10 markers), and
an implausibly large effect size (median genotypic rel-
ative risk = 1.28 and median minor allele frequency of
0.29),23 power was only 48%.
 The SZGene database contains records for 732 autoso-
mal genes from 1374 hypothesis-driven candidate gene
studies. These genes were studied from 1–81 times but
most genes (563, 76.9%) were investigated in 1 (60.9%)
or 2 studies (16.0%). Although replication is critical in
human genetics,21 there is little capacity to evaluate
both false positive and false negative findings.
 Genetic variation was typically poorly captured. For
technological or cost reasons, one or a few genetic
markers were assessed per gene. This approach cannot
capture even the common variation known to be pres-
ent nearly everywhere in the genome.
In sum, prior to 2008, the cytogenetic finding of an as-
sociation of SCZ with the 22q11.2 deletion was the only
robust and reproducible genetic association for SCZ.
What Do We Know Now?
GWAS have yielded a plethora of findings23,24 that meet
modern criteria for replication in human genetics.21 A
‘‘primer’’ is available.25 Since 2005, >700 GWAS have
been published; considering findings exceeding a conser-
vative significance threshold (P< 5 3 108), GWAS have
implicated ;1500 genetic markers for 101 human
diseases and 124 biomedical traits (eg, height, body
mass index (BMI), and lipid levels). GWAS have pro-
duced more etiological knowledge than virtually any
other technology in the history of medicine, save for clin-
ical microbiology and radiology.
There are 8 published SCZ GWAS of European sam-
ples that used individual-level genotyping26–33 (table 2).
In addition, 2 studies included African-American sam-
ples,31,33 one subjects of Japanese ancestry,34 and 2
used less reliable DNA pooling methods.35,36 By current
standards in human genetics, the sample sizes for virtu-
ally all of these studies are small. Therefore, the Psychi-
atric GWAS Consortium37 has conducted an integrated
mega-analysis of all available GWAS data on European
samples (Schizophrenia Psychiatric Genome-Wide Asso-
ciation Study Consortium, Submitted12).
In contrast to the paucity of findings from prior meth-
ods, GWAS has ‘‘worked’’ for SCZ in terms of identify-
ing common genetic variation that meet modern
standards for replication and significance in human
genetics. These findings include:
 Genetic variation in the extended major histocompat-
ibility complex (MHC) locus on chromosome 6 is as-
sociated with SCZ.27,31,32
 Genetic variation near MIR137 (the gene encoding the
microRNA miR-137) exceeds genome-wide signifi-
cance. At least 4 other genes exceeding genome-wide
significance contain predicted miR-137 binding sites
(Dr Stephan Ripke, oral presentation, World Congress
on Psychiatric Genetics, Athens, Greece, 6 October
2010). Given the likely role of miR-137 in neuronal de-
velopment and cross talk with epigenetic modification
machinery, these GWAS findings point at a novel,
plausible, and falsifiable hypothesis about the etiology
of SCZ.
 Additional loci with strong support include TCF4, a re-
gion of chr10, CSMD1, NGRN, and, in joint analyses
with bipolar disorder, ZNF804A, CACNA1C, and
ANK3.
 The above loci reach a conservative threshold for ge-
nome-wide significance intended to minimize false pos-
itive claims. There is evidence, however, that there are
hundreds and perhaps thousands of additional com-
mon loci that confer susceptibility to SCZ.27 A poly-
genic model from a SCZ discovery set replicated in 3
independent SCZ samples and, critically, did not rep-
licate in 6 nonpsychiatric biomedical disorders ruling
out many types of bias. This polygenic model has rep-
licated in a fourth independent sample of parent-af-
fected offspring trios, effectively ruling cryptic
population stratification.
 Copy number variants (CNVs) are rare but potent risk
factors for SCZ. CNVs that meet stringent criteria are
deletions in 22q11.21, 15q13.3, NRXN1, and 1q21.1
along with duplications in 16p11.2.18 All of these are
rare (present in 1–3 SCZ cases per 1000) but strong
risk factors for SCZ (genotypic relative risks of 7–
20). These large genomic changes are nonspecific,
and increase risk for multiple psychiatric, neurological,
and general medical disorders.15
 Several genetic architectures for SCZ can be excluded
with high confidence. SCZ is not exclusively caused by
rare variants of strong effect (ie, it is not a collection of
many different Mendelian disorders), and common
variants of strong effect in European samples are
very unlikely to exist.7,38
The MHC finding has been criticized as being due to
bias or artifact. However, the empirical results meet ac-
cepted criteria for replication in human genetics, the P
value exceeds chance by 10 0003, there are consistent
effects across samples, and appropriate control for pop-
ulation stratification does not explain away the
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association. Moreover, the MHC region has not emerged
in analyses of other psychiatric disorders (eg, attention-
deficit hyperactivity disorder, autism, bipolar disorder,
major depressive disorder, and smoking behavior) using
similar analytic methods and samples from overlapping
sites. The MHC region emerges in only ;25% of diseases
studied using GWAS (eg, multiple sclerosis (MS), rheu-
matoid arthritis, and systemic lupus erythematosus
[SLE]). The association of genetic variation in the
MHC with SCZ thus appears robust.
The Nature of the Beast
For the first time, we have a direct and empirical view of
the genetic architecture of SCZ. The data tell a clear
story—genetic variation for SCZ exists with frequencies
from very common to rare. The risk conveyed by these
variants is inversely associated with frequency. Empirical
data about the allelic spectrum of risk for SCZ are
depicted in Figure 1. In the upper left are rare CNVs
of strong effect, common variants of quite subtle effect
are on the lower right (red and yellow dots) and a poly-
genic signal (turquoise dots plus a blue best fit line).
The data that generated this graph provide an answer
to a question that has bedeviled SCZ genetics for a cen-
tury: is the syndromic entity SCZ a collection of rare
Mendelian/Mendelian-like disorders or is it due to a large
set of polygenes? SCZ is both.
The ‘‘map’’ of the genetic architecture of SCZ in Figure
1 is not the final draft. Larger GWAS will yield greater
numbers of significant loci. More comprehensive analyses
could yield more CNVs, and whole-genome, regional, and
exome-sequencing efforts might add loci that are uncom-
mon or rare.
What Lessons Have We Learned?
Very large samples are essential. Empirical data from
>200 different human traits provide guidance for the
determinants of the ‘‘success’’ of a GWAS. The single
most important factor is sample size: very large samples
by historical standards are required (a corollary is that
negative results from small studies are meaningless).
This relationship is illustrated in Figure 2 for SCZ.
Moreover, experience in human genetics indicates that
if sample size is sufficiently large, many loci become
Table 2. GWAS for SCZ in European Samples Using Individual Genotyping
First author Year
Stage 1 Stage 2
Ncases Ncontrols Significant regions Ncases Ncontrols Significant regions
Lencz 2007 178 144 0 — — —
O’Donovan 2008 642 2937 0 7308 12 834 0
Sullivan 2008 417 411 0 — — —
ISC 2009 3322 3587 1 8008 19 077 2
Need 2009 900 877 0 1592 2114 0
Shi 2009 2681 2653 0 8008 19 077 2
Stefansson 2009 2663 13 498 0 12 945 34 591 4
Athanasiu 2010 201 307 0 2864 14 087 0
PGC — 9394 12 462 2 17 836 33 859 8
Fig. 1.The allelic spectrum of SCZ. Y-axis is genotypic relative risk, and x-axis is the risk allele prevalence (both log10 scale). In the upper left
are rare CNVs of strong effect, common variants of quite subtle effect are on the lower right (red and yellow dots) and a polygenic signal
(turquoise dots plus a blue best fit line). The inset expands the lower right to provide gene names.
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highly confident and pathways emerge that beautifully
illuminate biology.39,40
Combining data across samples is valid. One argument
that is not supported by data is that combining samples
across different sites and countries will introduce crip-
pling heterogeneity or bias. This argument has little sup-
port because there are dozens of examples where
different studies have been combined to augment power.
For example, height is surprisingly difficult to assess and
yet a meta-analysis of 46 studies yielded compelling and
coherent genetic results.39
Obey the laws of probability. Basic algebra classes in-
clude combinatorics and elementary probability. Appli-
cation of these basic mathematical principles yields
a conclusion of exceptional relevance to psychiatric ge-
netics: gambling is not a strategy for progress. More spe-
cifically, everyone has to pay the price of multiple
comparisons to avoid crippling type 1 error,22 integrated
replication is essential,21 and underpowered studies are
not worth doing. These principles are widely known
but not universally appreciated.
Highly significant and replicated loci for SCZ typically
have genotypic relative risks ;1.10. For replication of
a specific association, the effect size in an initial study
overestimates the actual value (ie, ‘‘winner’s curse’’)41
and high power is desired (90%). For one maker,
11 000 subjects are required (5500 cases and 5500 con-
trols). Sample sizes increase to 17 500 subjects for 10
markers and 24 000 subjects for 100 markers. These sam-
ple sizes are more than an order of magnitude larger than
historically typical for the SCZ candidate gene associa-
tion field.
Hypothesis-driven approaches have not generally
worked. In human complex disease genetics, empirical
results have identified ‘‘usual suspects’’42 such as the
MHC locus for type 1 diabetes mellitus (T1DM) or
APOE for Alzheimer’s disease. However, these examples
are infrequent, and the vast majority of high-confidence
results from genetic studies point to unsuspected loci.
Therefore, SCZ researchers need to question seriously
our most cherished ideas about the etiology of SCZ.
We recently evaluated historical candidate genes for
SCZ in comparison to GWAS findings and found essen-
tially no overlap. The hypothesis-driven candidate genes
for SCZ that have been studied the most had no indica-
tion of common-variant signal (ie, COMT, DRD3,
DRD2, HTR2A, NRG1, BDNF, DTNBP1, and
SLC6A4) (Collins et al, Submitted10). The status of
‘‘the special gene,’’ DISC1, is particularly unclear: there
is no common-variant signal, rare variation has not been
found in resequencing of large samples, and reevaluation
of the initial report suggests the name ‘‘disrupted in SCZ’’
is a misnomer. In this carefully assessed pedigree, the pro-
positus had conduct disorder, and SCZ is a minor phe-
notype associated with the (1;11)(q42;q14.3)
translocation (38% normal/other, 34% recurrent major
depression, and 24% SCZ).43
What Should We Do Next?
In the complex and difficult history of SCZ genetics,
many different technological approaches have been tried
(table 1). To date, however, the only proven approaches
are GWAS and assessment of CNVs. Should we push for
more GWAS for SCZ?
First, as noted above, GWAS has an impressive track
record of success in human complex disease genetics as
well as in SCZ genetics. It has delivered where most other
technologies have failed. Second, GWAS is a mature and
inexpensive technology. Quality control, imputation, and
analysis are readily accomplished. There are large
amounts of data that can be used for comparisons.
The cost can be as low as $250/sample. Third, most
GWAS arrays contain single nucleotide polymorphisms
(SNP) content sufficient to capture the majority of com-
mon variation in European and many other world pop-
ulations along with content for large CNVs.
Fourth, we have empirical data that allow prediction of
what might be discovered if we were to conduct GWAS
on more SCZ cases. Given that research on the genetics of
SCZ is 3–4 years behind other biomedical diseases, we
can look at the data for SCZ in relation to other complex
human traits instead of relying on assumption-laden pre-
dictions. We used the NHGRI GWAS catalog23 to iden-
tify studies for 11 complex traits including SCZ. We
reviewed 104 studies and included 72 (individual ge-
nome-wide genotyping of European subjects). Each
study was reviewed at least twice to capture the number
of cases analyzed and the number of genomic regions that
exceeded genome-wide significance (P < 5 3 108). For
each trait, we fit a regression line (number of regions ;
number of cases) to estimate the relation of these varia-
bles. There was a significant relation for 8 of the 11 traits.
The estimates in table 3 reveal intriguing lessons about
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Fig. 2.Relation between number of genome-wide significant regions
and number of cases for 8 GWAS of SCZ.
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a glimpse into their genetic architectures. The slope esti-
mates (ie, the number of genome-wide significant regions
per 1000 cases) vary widely, from 0.1 for BMI to over 3
for Crohn’s disease and SLE. Intriguingly, SCZ is in the
middle of the pack and about the same as T2DM, lung
cancer, age-related macular degeneration (AMD), and
MS. However, when we estimate the number of cases re-
quired before the first genome-wide significant result,
SCZ is the worst of the complex diseases in table 3
(the continuous traits of height and BMI are on a different
scale). This is also apparent in Figure 2 where a ‘‘hockey-
stick’’ relation can be imagined. The major correlates of
the number of significant regions are sample size and her-
itability (Spearman q both ;0.6). Because heritability is
not under experimental control, increasing sample size is
therefore the way to increase the yield of GWAS (on av-
erage).
The estimates in table 3 encapsulate broad aspects of
the genetic architectures of these traits (ie, the number of
loci and effect size distributions as well as the inherent
noisiness of phenotypic assessment). We do not see evi-
dence that SCZ is qualitatively different save for a higher
minimum number of cases to first detection (which we
suspect reflects that there is no common genetic variant
of strong effect as for AMD and T1DM combined with
phenotype imprecision). SCZ is wonderfully typical.
What would happen if the numbers of SCZ cases were
increased? In order to achieve the power of the most suc-
cessful GWAS to data,39 50 000 SCZ cases and 50 000
controls are required (Ya44 Around 12 000 SCZ cases
with GWAS data are now available. If the sample size
were increased to 100 000, there would be 2 immediate
yields: the number of loci exceeding genome-wide signif-
icance can be predicted to total 21 and, equally impor-
tant, the rank order of the SNPs would greatly
improve meaning that pathway analyses would become
far more reliable.
Continuing with GWAS would be one of the better
bets for progress in the history of SCZ genetic research.
Should We Care if R2 is Low?
For many complex traits, the amount of variance due to
genome-wide significant loci (R2) is a small portion of the
overall heritability (<10%). Some have argued that this
‘‘missing heritability’’ is a reason why GWAS has failed
and that their results do not matter.
We do not find this objection compelling. First, the goal
of genetic studies of SCZ is to find pathways and loci that
are strongly and robustly associated with disease. R2
should not be the criterion for success because it is more
relevant for individualized medicine (a distal not proximal
goal). Second, we have remarkably poor heritability esti-
mates for many complex traits meaning that this criterion
is imprecise and subject to bias. Third, if sample sizes are
too small, the genome-wide significance bar is conservative,
and the impact of true effects that are not quite significant
are missed. This issue is compounded by the fact that the
current generation of GWAS SNP arrays imperfectly as-
sess common genetic variation. If analyses account for
these considerations, it can be seen that heritability is ‘‘hid-
den’’ rather than missing.45,27,38 Indeed, 2 independent
analyses suggest that common variants account for about
a third of the variance in liability for SCZ.
Finally, some have argued that GWAS findings that do
not have immediately obvious functional significance are
irrelevant. This is a weak argument. Appropriate exper-
imentation is required, and the literature is replete with
examples of GWAS findings of mechanistic importance
that emerged only after follow-up molecular work.
What About Sequencing?
There have been spectacular advances in sequencing tech-
nologies. It is now feasible to resequence all known exons
Table 3. Numbers of Cases and Significant Regions in 72 Studies of 11 Complex Traits
Trait Heritability Studies Loci Max Ncase Slope/1000 cases N-to-first P value
BMI 0.59 5 32 249 746 0.1 20 500 0.002
Breast CA 0.25 6 8 26 258 0.2 1050 0.05
T2DM 0.26 8 14 42 542 0.3 3273 0.0007
Lung CA 0.08 8 3 7560 0.4 3350 0.001
SCZ 0.81 9 8 17 836 0.4 4950 0.0004
AMD 0.46 4 7 6,777 0.5 50 ns
MS 0.41 8 6 4839 0.5 260 ns
Height 0.81 9 180 183 727 1.1 22 709 0.000005
T1DM 0.88 3 15 12 385 1.3 1592 ns
Crohn’s 0.60 6 71 22 027 3.1 1248 0.01
SLE 0.44 6 12 2552 3.5 86 0.02
Note: Abbreviations. BMI, body mass index; CA, cancer; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; AMD, age-
related macular degeneration; MS, multiple sclerosis; SLE, systemic lupus erythematosus. Slope is in units of number of number of
genome-wide significant regions per 1000 cases. N-to-first is the number of cases required to get the first genome-wide significant
finding. P value is the significance of the slope.
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and even whole genomes. Costs are likely to decline but
these are expensive technologies. At the time of this writ-
ing in Q1/2011, confident sequencing of an exome costs
about $US 3000 and a genome costs $12 000. In the ideal
situation, we would obtain genome resequencing for
large collections of SCZ cases.
Does it make sense to shift direction entirely to se-
quencing as some have argued? It is unfortunate that se-
quencing has already been the focus of considerable
‘‘hype’’ (in contrast to GWAS where many investigators
argued for conservative expectations).46 There are rea-
sons for caution, and we need to be mindful of painfully
learned lessons from the past.
Psychiatric genetics has always underestimated the
necessary sample sizes by several orders of magnitude.
Although sequencing can discover causes of Mendelian
disorders in small samples,44 SCZ is unlikely to have
Mendelian subforms. Quick successes are unlikely, and
sequencing efforts could prove to be far more complex
than predicted and very large samples are likely to be re-
quired. Exome and whole-genome sequencing works best
if SCZ is caused exclusively or nearly so by rare variants
that are not readily detected using the current generation
of genotyping arrays. This strong assumption is inconsis-
tent with empirical data.38
Sequencing is an appealing technology. However, we
need to be realistic about what it might yield, and pay
particular attention to its underlying assumptions and
limitations. We need to be a bit jaded and worldly:
many shiny new technologies have been applied to
SCZ with great fanfare that ultimately failed to deliver.
We should be interested, appropriately skeptical, and
resist efforts to rely on a single technological approach.
The Take-Home
The main goal of genetic studies of SCZ is to identify
pathways that confer risk and protection. For the first
time, there is demonstrable progress toward this end as
SCZ appears to be a relatively highly polygenic disease.
If this knowledge is developed far more completely, we
may be able to describe the basic mechanisms that go
awry in the pathogenesis of SCZ (eg, the miR-137
hypothesis described above). Such knowledge can deliver
compelling biological hypotheses to fuel more refined
and specific investigations into the causes of SCZ.
Genetic approaches—particularly GWAS—are work-
ing. The field needs to stay focused on what has worked in
order to maximize progress.
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